Wolff Stefani
EVP and COO at NRIX; Chief Development Officer at Principia Biopharma Inc.
- Sold, on record
- $883k
- Dollars the filings state
- Form 4 sales
- 8
- Latest May 1, 2023
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- NRIXNurix Therapeutics, Inc.EVP and COO
- Principia Biopharma Inc.Chief Development Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Principia Biopharma Inc.16,513 shares
- NRIX1,802 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Principia Biopharma Inc.Plan not statedDec 16 2019
Sold 5,505 shares at $49.43 ($272k)
Wolff Stefani, Chief Development Officer
Sold 13.4% of holdings ($2M position)35,609 shares leftFirst sale on recordFiling
- 2 Form 4 sale Principia Biopharma Inc.Plan not statedMar 16 +91 days
Sold 5,504 shares at $46.16 ($254k)
Wolff Stefani, Chief Development Officer
Sold 13.4% of holdings ($1.9M position)35,609 shares leftFiling
- 3 Form 4 sale Principia Biopharma Inc.Plan not statedJun 15 +91 days
Sold 5,504 shares at $60.75 ($334k)
Wolff Stefani, Chief Development Officer
Sold 22.4% of holdings ($1.5M position)19,096 shares leftFiling
- 4 Form 4 sale NRIXUnusualMay 2 +686 days
Sold 330 shares at $11.75 ($4k)
Wolff Stefani, EVP and COO
Sold 34.3% of holdings ($11k position)632 shares leftFirst sale on recordFiling
- 5 Form 4 sale NRIXPlan not statedAug 1 +91 days
Sold 356 shares at $15.67 ($6k)
Wolff Stefani, EVP and COO
Sold 22.3% of holdings ($25k position)1,238 shares leftFiling
- 6 Form 4 sale NRIXPlan not statedOct 31 +91 days
Sold 350 shares at $12.88 ($5k)
Wolff Stefani, EVP and COO
Sold 9.3% of holdings ($48k position)3,402 shares leftFiling
- 7 Form 4 sale NRIXPlan not statedJan 30 +91 days
Sold 424 shares at $11.78 ($5k)
Wolff Stefani, EVP and COO
Sold 9.7% of holdings ($51k position)3,940 shares left1.2x usual sizeFiling
- 8 Form 4 sale NRIXNo planMay 1 +91 days
Sold 342 shares at $9.88 ($3k)
Wolff Stefani, EVP and COO
No 10b5-1 planSold 5.3% of holdings ($64k position)6,113 shares left1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (8)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| May 1, 2023 | NRIX | EVP and COO | Form 4 sale | 342 | $3k | 5.3% | No plan | SEC |
| Jan 30, 2023 | NRIX | EVP and COO | Form 4 sale | 424 | $5k | 9.7% | Plan not stated | SEC |
| Oct 31, 2022 | NRIX | EVP and COO | Form 4 sale | 350 | $5k | 9.3% | Plan not stated | SEC |
| Aug 1, 2022 | NRIX | EVP and COO | Form 4 sale | 356 | $6k | 22.3% | Plan not stated | SEC |
| May 2, 2022 | NRIX | EVP and COO | Form 4 sale | 330 | $4k | 34.3% | Unusual | SEC |
| Jun 15, 2020 | Principia Biopharma Inc. | Chief Development Officer | Form 4 sale | 5,504 | $334k | 22.4% | Plan not stated | SEC |
| Mar 16, 2020 | Principia Biopharma Inc. | Chief Development Officer | Form 4 sale | 5,504 | $254k | 13.4% | Plan not stated | SEC |
| Dec 16, 2019 | Principia Biopharma Inc. | Chief Development Officer | Form 4 sale | 5,505 | $272k | 13.4% | Plan not stated | SEC |